STK33，即絲氨酸/蘇氨酸激酶33，它是一種在人體多種組織中表達的蛋白激酶，屬于鈣/鈣調(diào)蛋白依賴性激酶家族成員。STK33在細(xì)胞中的表達受細(xì)胞密度控制，并且在頭頸腫瘤等手術(shù)切除標(biāo)本中的表達量顯著高于正常或癌旁組織。其作用機制涉及自磷酸化功能，能夠?qū)ο掠位蛉鏥imentin蛋白進行磷酸化修飾，影響其生物學(xué)功能。STK33還可能通過非激酶活性依賴途徑影響C-Myc基因的轉(zhuǎn)錄作用。在信號通路方面，STK33與ERK1/2信號通路存在交互作用，可能參與調(diào)控細(xì)胞增殖、侵襲和轉(zhuǎn)移。STK33的生物學(xué)意義在于其在腫瘤細(xì)胞的增殖、侵襲與轉(zhuǎn)移等過程中的重要作用，尤其在KRAS突變相關(guān)的腫瘤中，STK33的表達與腫瘤細(xì)胞的生物學(xué)行為密切相關(guān)。因此，STK33被認(rèn)為是多種癌癥治療的潛在靶點。

熱銷產(chǎn)品

STK33 Recombinant Monoclonal Antibody (CSB-RA207790A0HU)

驗證數(shù)據(jù)

IHC image of CSB-RA207790A0HU diluted at 1:100 and staining in paraffin-embedded human liver cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB.